about
Hematopoietic stem cell transplantation for people with sickle cell diseaseHematopoietic stem cell transplantation for people with sickle cell diseaseHematopoietic stem cell transplantation for children with sickle cell diseaseNovel insights in the management of sickle cell disease in childhoodHematopoietic stem cell transplantation in sickle cell disease: patient selection and special considerationsSickle cell disease in childrenAdvances in sickle cell therapies in the hydroxyurea eraManagement of sickle cell disease: recent advances and controversies.How I manage cerebral vasculopathy in children with sickle cell disease.Magnetic resonance imaging in pediatric sickle cell anemia.Improved cerebrovascular patency following therapy in patients with sickle cell disease: initial results in 4 patients who received HLA-identical hematopoietic stem cell allografts.Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel.Mouse nidovirus LDV infection alleviates graft versus host disease and induces type I IFN-dependent inhibition of dendritic cells and allo-responsive T cells.Mechanisms of lung injury after bone marrow transplantation.Clinical applications of mixed chimerism.Impact of family income and sickle cell disease on the health-related quality of life of children.Acute chest syndrome in sickle cell disease. Crucial considerations in adolescents and adults.Reduction of intramedullary apoptosis after stem cell transplantation in black african variant of pediatric sickle cell anemia.The emerging understanding of sickle cell disease.Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell diseaseAllogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis.Zinc finger nucleases for targeted mutagenesis and repair of the sickle-cell disease mutation: An in-silico study.Pediatric hematology providers on referral for transplant evaluation for sickle cell disease: a regional perspective.Sickle cell disease expenditures and outcomes.Hematopoietic stem cell transplantation for patients with sickle cell disease: progress and future directions.Sickle cell disease: the neurological complications.Need for cognitive rehabilitation for children with sickle cell disease and strokes.Increased reticulocytosis during infancy is associated with increased hospitalizations in sickle cell anemia patients during the first three years of life.Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma.Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial.Therapeutic challenges in childhood sickle cell disease. Part 1: current and future treatment options.Therapeutic challenges in childhood sickle cell disease. Part 2: a problem-orientated approach.Stem cell transplantation for sickle cell disease: can we reduce the toxicity?HLA-identical stem cell transplantation: is there an optimal CD34 cell dose?Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now.Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. French Study Group on Sickle Cell Disease.PedsQL™ sickle cell disease module: feasibility, reliability, and validity.Haematopoietic cell transplantation in the treatment of sickle cell disease.Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.New insights into haematopoietic stem cell transplantation for patients with haemoglobinopathies.
P2860
Q24185759-3DFC8303-8B7E-423B-85E7-409F82E44590Q24202852-81A27CEF-C26E-45C0-9B29-84B9F10E678EQ24240994-5D492533-994E-488E-8D83-4D7A46EFCEFEQ26767015-40DBA396-4D1C-432B-8073-21285D02C283Q26800236-BE7784C0-59FB-4268-9949-18BC33E7E95FQ26864582-088FE2CE-F814-40A9-B2F1-96D267ACF4B8Q28088552-A51BCAEB-009F-4A3D-8480-967972CDC34FQ30790662-73EBA41C-B610-4275-AC12-71C4A4C3E39BQ30945117-160ED542-5A7C-4B12-AC54-EFE33D3FEB9BQ31116644-91B33F5A-DDD0-46E4-AFBC-7C88C15A6C72Q32061178-BA45E18F-155B-4C1B-B52B-6650F984FA02Q33558770-7371851B-F608-4146-AD8A-20083F381BBAQ33638762-29E07152-F6A3-4148-AB2B-36D9AA0C314FQ33642996-59E513BB-B620-43D9-989E-160140AF333DQ33661943-CC98BFDA-D9F7-4330-A58F-4C6D37E30ACCQ33735436-412C645D-6719-49CD-AD1D-61E93D1D0A3DQ33825516-9D3188F1-C55B-48FE-A14D-FD5AD75D436BQ33920142-A659C644-92FE-4C00-BC05-1D9BD400223DQ33932507-0CBFD5F8-9870-4EDB-BACA-7E1FC1D549F7Q34057698-83925A74-DC29-4717-A923-075AB6BFDD53Q34207677-6BCB15B1-AD7F-47C4-804A-225A6E954A8CQ34268053-52B31682-5B9B-4B12-B071-FA1396EC1FDAQ34336920-DC6C256C-18AA-4AB2-BE5A-244ED729E069Q34404985-B5287636-DB14-4118-AB11-196009622897Q34625467-7470D554-4719-4FE6-854F-97784F49CA90Q34733113-8569FD9F-BD37-43D6-8C25-778083ACA398Q34749681-19586AE2-D51D-44B1-BE25-A1B7EFF9E45FQ34947693-F764C3FC-A482-4DB0-BC0E-6B4ED064F2E7Q35022491-AE2B942E-DAD8-42ED-9727-F2B8E9F69374Q35073850-DEA3FF4C-AE0F-409D-9BE3-14364091D247Q35076604-D5F0ACFF-6C91-41FF-9BB8-4DB0FC7AD70DQ35076607-91BC8113-B64C-4A16-943E-48164C15AD73Q35098099-BFFC8BC5-B00B-4ECF-8CD5-ABEEB91F8B01Q35128241-0874E896-35A4-4825-B208-44056A975FAAQ35153756-63F01CB7-D579-4441-A006-7DAE0DC631E2Q35265107-38BF29C5-CF3D-4D4B-A86D-AF4C3E892240Q35545910-9036BAB1-22B1-46E1-B4D9-312E4E65EA76Q35594060-FFCBEC34-13C7-4224-83B9-9C967E758878Q35615734-C5AC5AE7-2A94-45A5-8055-ADA8B7ACF0CAQ35688840-3F5EF4EA-2BE1-4BFB-9F73-BF3D6FDE7BB5
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Bone marrow transplantation for sickle cell disease.
@en
Bone marrow transplantation for sickle cell disease.
@nl
type
label
Bone marrow transplantation for sickle cell disease.
@en
Bone marrow transplantation for sickle cell disease.
@nl
prefLabel
Bone marrow transplantation for sickle cell disease.
@en
Bone marrow transplantation for sickle cell disease.
@nl
P2093
P1476
Bone marrow transplantation for sickle cell disease.
@en
P2093
Bernaudin F
Leisenring W
Matthews DC
Mentzer WC
Ohene-Frempong K
Patience M
Sullivan KM
P304
P356
10.1056/NEJM199608083350601
P407
P577
1996-08-01T00:00:00Z